GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (NAS:EMBC) » Definitions » ROCE %

Embecta (Embecta) ROCE % : 16.94% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Embecta's annualized ROCE % for the quarter that ended in Mar. 2024 was 16.94%.


Embecta ROCE % Historical Data

The historical data trend for Embecta's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta ROCE % Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
ROCE %
- 80.83 80.80 42.97 25.84

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.44 21.92 15.10 19.18 16.94

Embecta ROCE % Calculation

Embecta's annualized ROCE % for the fiscal year that ended in Sep. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=212.7/( ( (1086.4 - 301) + (1214.4 - 353.5) )/ 2 )
=212.7/( (785.4+860.9)/ 2 )
=212.7/823.15
=25.84 %

Embecta's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=150.8/( ( (1217.8 - 326.6) + (1199.6 - 310.4) )/ 2 )
=150.8/( ( 891.2 + 889.2 )/ 2 )
=150.8/890.2
=16.94 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embecta  (NAS:EMBC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Embecta ROCE % Related Terms

Thank you for viewing the detailed overview of Embecta's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (Embecta) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Executives
David F Melcher director 1650 TYSONS BOULEVARD, SUITE 1700, MCLEAN VA 22102
Devdatt Kurdikar officer: President and CEO ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jacob Elguicze officer: Chief Financial Officer ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jeffrey Z Mann officer: SVP, GC, Head Corp. Dev., Secy 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Jean Casner officer: Chief Human Resources Officer 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Ajay Kumar officer: SVP and CHRO C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Shaun Curtis officer: SVP, Global Manuf./Sup. Chain C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
David Albritton director ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417-1880
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Brian Capone officer: VP, CAO & Corp. Controller 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Carrie L Anderson director 3005 HIGHLAND PARKWAY, SUITE 200, DOWNERS GROVE IL 60515
Claire Pomeroy director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Christopher R Reidy director ONE ADP BLVD, ROSELAND NJ 07068
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015